CG
TVRD

Carmignac Gestion’s Tvardi Therapeutics TVRD Stock Holding History

Carmignac Gestion’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Hold
0
– -$9.79M – 151
2021
Q1 		– Hold
0
– – – 70

Other funds holding TVRD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Carmignac Gestion's TVRD Position: Q3 2021 in Review

Carmignac Gestion sold out of Tvardi Therapeutics (TVRD) in Q3 2021, closing a stake of 4,059 shares — an estimated $2.08M sold.

Carmignac Gestion first reported a position in TVRD in Q2 2018 and held it in 13 quarters. The position peaked at $35.3M in Q2 2020. 170 funds tracked by Wall St. Rank hold TVRD as of Q3 2021.

  • Carmignac Gestion reported no remaining Tvardi Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Carmignac Gestion sold 4,059 Tvardi Therapeutics shares in Q3 2021, an estimated $2.08M.
  • Carmignac Gestion first reported a position in Tvardi Therapeutics in Q2 2018 and held it in 13 quarters.
  • Carmignac Gestion's Tvardi Therapeutics position peaked at $35.3M in Q2 2020.
  • 170 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2021.

Based on Carmignac Gestion's 13F filing for Q3 2021, filed 12 Nov 2021.